Aurinia Pharmaceuticals (AUPH) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aurinia Pharmaceuticals Inc. is set to engage with investors through one-on-one meetings at two key healthcare conferences in July 2024, showcasing their commitment to addressing autoimmune diseases with groundbreaking therapies like their FDA-approved LUPKYNIS for lupus nephritis. The company’s global development efforts are anchored by their Canadian headquarters and their U.S. commercial office.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.